Skip to main content

Table 2 Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in intravenous immunoglobulin (IVIG) responding or non-responding patients with Kawasaki disease

From: Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease

Characteristic IVIG responders (n= 36) IVIG non-responders (n= 4) P
Boys/girls, number 21/15 1/3 0.000
Age, months 22.4 (17.2) 30.5 (12.8) 0.000
Patients with CALs, number 7 2 0.000
Resistin, 102 ng/ml Acute stage 0.35 (0.24) 0.64 (0.30) 0.032
  Afebrile stage 0.21 (0.19) ** 0.48 (0.35) 0.019
  Subacute stage 0.12 (0.05) **▲ 0.28 (0.19) 0.000
S100A12, 102 ng/ml Acute stage 5.05 (3.22) 7.92 (2.61) 0.044
  Afebrile stage 3.99 (3.49) 4.80 (4.26) 0.668
  Subacute stage 2.35 (2.26)** ▲ 4.98 (4.75) 0.047
sRAGE, 102 pg/ml Acute stage 3.07 (1.98) 2.37 (0.96) 0.493
  Afebrile stage 6.00 (2.78)** 3.51 (2.64) 0.046
  Subacute stage 7.19 (2.88)** 3.65 (3.27) 0.026
  1. Results are mean (SD) unless stated otherwise. CALs, coronary artery lesions; **P < 0.01 compared with acute stage; ▲P < 0.05 compared with afebrile stage.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us